SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-048894
Filing Date
2020-10-29
Accepted
2020-10-29 16:30:34
Documents
14
Period of Report
2020-10-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eidx-8k_20201029.htm   iXBRL 8-K 40995
2 EX-99.1 eidx-ex991_6.htm EX-99.1 395921
3 GRAPHIC gkk5m0i3k1jp000001.jpg GRAPHIC 2631
  Complete submission text file 0001564590-20-048894.txt   594162

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eidx-20201029.xsd EX-101.SCH 5756
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eidx-20201029_lab.xml EX-101.LAB 20227
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eidx-20201029_pre.xml EX-101.PRE 12069
7 EXTRACTED XBRL INSTANCE DOCUMENT eidx-8k_20201029_htm.xml XML 3673
Mailing Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 650-391-9740
Eidos Therapeutics, Inc. (Filer) CIK: 0001731831 (see all company filings)

IRS No.: 463733671 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38533 | Film No.: 201273048
SIC: 2834 Pharmaceutical Preparations